169 related articles for article (PubMed ID: 29730200)
1. Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors.
Mäkelä VJ; Kotsar A; Tammela TLJ; Murtola TJ
J Urol; 2018 Oct; 200(4):743-748. PubMed ID: 29730200
[TBL] [Abstract][Full Text] [Related]
2. Association of Suicidality and Depression With 5α-Reductase Inhibitors.
Welk B; McArthur E; Ordon M; Anderson KK; Hayward J; Dixon S
JAMA Intern Med; 2017 May; 177(5):683-691. PubMed ID: 28319231
[TBL] [Abstract][Full Text] [Related]
3. 5α-reductase inhibitors and the risk of bladder cancer in a large, population-based cohort.
Dekalo S; McArthur E; Campbell J; Ordon M; Power N; Welk B
Urol Oncol; 2023 Jan; 41(1):50.e11-50.e17. PubMed ID: 36319553
[TBL] [Abstract][Full Text] [Related]
4. The Use of 5-Alpha Reductase Inhibitors and Alpha-1 Blockers Does Not Improve Clinical Outcome in Male Patients Undergoing Radical Cystectomy for Bladder Cancer in Quebec, Canada.
Wissing MD; O'Flaherty A; Dragomir A; Tanguay S; Kassouf W; Aprikian AG
Clin Genitourin Cancer; 2021 Aug; 19(4):371-371.e9. PubMed ID: 33676834
[TBL] [Abstract][Full Text] [Related]
5. Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features.
Dai C; Ganesan V; Zabell J; Nyame YA; Almassi N; Greene DJ; Hettel D; Reichard C; Haywood SC; Arora H; Zampini A; Crane A; Li J; Elshafei A; Magi-Galluzzi C; Stein RJ; Fareed K; Gong M; Jones JS; Klein EA; Stephenson AJ
J Urol; 2018 Feb; 199(2):445-452. PubMed ID: 28789947
[TBL] [Abstract][Full Text] [Related]
6. 5α-Reductase Inhibitors and Risk of Prostate Cancer Death.
Bonde Miranda T; Garmo H; Stattin P; Robinson D
J Urol; 2020 Oct; 204(4):714-719. PubMed ID: 32243243
[TBL] [Abstract][Full Text] [Related]
7. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study.
Wei L; Lai EC; Kao-Yang YH; Walker BR; MacDonald TM; Andrew R
BMJ; 2019 Apr; 365():l1204. PubMed ID: 30971393
[TBL] [Abstract][Full Text] [Related]
8. A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride.
Antoniou T; Macdonald EM; Yao Z; Gomes T; Tadrous M; Ho JM; Mamdani MM; Juurlink DN;
BMC Musculoskelet Disord; 2018 May; 19(1):160. PubMed ID: 29789004
[TBL] [Abstract][Full Text] [Related]
9. Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5α-Reductase Inhibitor.
Shiota M; Kiyoshima K; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Takahashi R; Inokuchi J; Tatsugami K; Eto M
J Urol; 2017 Feb; 197(2):308-313. PubMed ID: 27506696
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use.
Murtola TJ; Virkku A; Talala K; Stenman UH; Taari K; Tammela TLJ; Auvinen A
J Urol; 2017 Aug; 198(2):305-309. PubMed ID: 28216328
[TBL] [Abstract][Full Text] [Related]
11. Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.
Dutta A; Panja S; Virk RK; Kim JY; Zott R; Cremers S; Golombos DM; Liu D; Mosquera JM; Mostaghel EA; Barbieri CE; Mitrofanova A; Abate-Shen C
Eur Urol; 2017 Oct; 72(4):499-506. PubMed ID: 28385453
[TBL] [Abstract][Full Text] [Related]
12. Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide.
Garcia-Argibay M; Hiyoshi A; Fall K; Montgomery S
JAMA Netw Open; 2022 Dec; 5(12):e2248135. PubMed ID: 36547981
[TBL] [Abstract][Full Text] [Related]
13. Lack of Association between 5α-Reductase Inhibitors and Depression.
Dyson TE; Cantrell MA; Lund BC
J Urol; 2020 Oct; 204(4):793-798. PubMed ID: 32294395
[TBL] [Abstract][Full Text] [Related]
14. 5α-reductase inhibitors impact prognosis of urothelial carcinoma.
Wang CS; Li CC; Juan YS; Wu WJ; Lee HY
BMC Cancer; 2020 Sep; 20(1):872. PubMed ID: 32917158
[TBL] [Abstract][Full Text] [Related]
15. Association of 5α-Reductase Inhibitor Prescription With Bladder Cancer Progression in Males in South Korea.
An MH; Kim MS; Kim C; Noh TI; Joo KJ; Lee DH; Yi KH; Kwak JW; Hwang TH; Park RW; Kang SH
JAMA Netw Open; 2023 May; 6(5):e2313667. PubMed ID: 37191958
[TBL] [Abstract][Full Text] [Related]
16. Finasteride does not prevent bladder cancer: A secondary analysis of the Medical Therapy for Prostatic Symptoms Study.
Sathianathen NJ; Fan Y; Jarosek SL; Lawrentschuk NL; Konety BR
Urol Oncol; 2018 Jul; 36(7):338.e13-338.e17. PubMed ID: 29731413
[TBL] [Abstract][Full Text] [Related]
17. The Genomic Alterations of 5α-Reductases and Their Inhibitor Finasteride's Effect in Bladder Cancer.
Chen CC; Huang CP; Tsai YT; Hseih TF; Shyr CR
Anticancer Res; 2017 Dec; 37(12):6893-6898. PubMed ID: 29187470
[TBL] [Abstract][Full Text] [Related]
18. Male breast cancer and 5α-reductase inhibitors finasteride and dutasteride.
Bird ST; Brophy JM; Hartzema AG; Delaney JA; Etminan M
J Urol; 2013 Nov; 190(5):1811-4. PubMed ID: 23665270
[TBL] [Abstract][Full Text] [Related]
19. 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.
Murtola TJ; Karppa EK; Taari K; Talala K; Tammela TL; Auvinen A
Int J Cancer; 2016 Jun; 138(12):2820-8. PubMed ID: 26804670
[TBL] [Abstract][Full Text] [Related]
20. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
